Nihon Keizai Shimbun Published the Article on the Results of Phase II Malignant Melanoma Study

We announced the results of a Phase II study of RS5614, a PAI-1 inhibitor, in melanoma on August 16, 2023. We are pleased to inform that an article on the study results was published in the Nihon Keizai Shimbun (electronic edition).

Please see the following release information for IR article on the results of the Phase II malignant melanoma trial of our PAI-1 inhibitor.

PAI-1 Inhibitor RS5614 Met Primary Endpoint in Phase II InvestigatorInitiated Clinical Trial for Malignant Melanoma Refractory to Nivolmab